VEGFR-IN-1 | VEGFR Tyrosine Kinase Inhibitor II | VEGF Inhibitor

首页 / / / / VEGFR-IN-1

VEGFR-IN-1 {[allProObj[0].p_purity_real_show]}

货号：A204345 同义名： VEGFR Tyrosine Kinase Inhibitor II;Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor II

VEGFR-IN-1是一种高效的血管生成抑制剂，能够抑制 KDR、Flt-1、c-Kit、EGF-R 和 c-Src，IC₅₀ 分别为 0.02、0.18、0.24、7.3 和 7 µM，适用于与血管生成相关的癌症及其他疾病的研究。

VEGFR-IN-1 化学结构
CAS号：269390-69-4

VEGFR-IN-1 3D分子结构
CAS号：269390-69-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

VEGFR-IN-1 纯度/质量文件产品仅供科研

货号：A204345 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

VEGFR 亚型比较
EGFR 亚型比较
c-Kit 亚型比较

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	{[allProObj[0].p_purity_real_show]}
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		{[allProObj[0].p_purity_real_show]}
Brivanib	+ VEGFR1, IC50: 380 nM	++ VEGFR2, IC50: 25 nM Flk1, IC50: 25 nM			{[allProObj[0].p_purity_real_show]}
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	{[allProObj[0].p_purity_real_show]}
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,c-Kit,PDGFR	{[allProObj[0].p_purity_real_show]}
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		{[allProObj[0].p_purity_real_show]}
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	{[allProObj[0].p_purity_real_show]}
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	{[allProObj[0].p_purity_real_show]}
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	{[allProObj[0].p_purity_real_show]}
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	{[allProObj[0].p_purity_real_show]}
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	{[allProObj[0].p_purity_real_show]}
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			{[allProObj[0].p_purity_real_show]}
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	{[allProObj[0].p_purity_real_show]}
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	{[allProObj[0].p_purity_real_show]}
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	{[allProObj[0].p_purity_real_show]}
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			{[allProObj[0].p_purity_real_show]}
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		{[allProObj[0].p_purity_real_show]}
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		{[allProObj[0].p_purity_real_show]}
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	{[allProObj[0].p_purity_real_show]}
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	{[allProObj[0].p_purity_real_show]}
BMS-794833		++ VEGFR2, IC50: 15 nM			{[allProObj[0].p_purity_real_show]}
SKLB1002		++ VEGFR2, IC50: 32 nM			{[allProObj[0].p_purity_real_show]}
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			{[allProObj[0].p_purity_real_show]}
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	{[allProObj[0].p_purity_real_show]}
SU 5402		++ VEGFR2, IC50: 20 nM			{[allProObj[0].p_purity_real_show]}
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	{[allProObj[0].p_purity_real_show]}
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			{[allProObj[0].p_purity_real_show]}
LY2874455		+++ VEGFR2, IC50: 7 nM			{[allProObj[0].p_purity_real_show]}
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			{[allProObj[0].p_purity_real_show]}
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	{[allProObj[0].p_purity_real_show]}
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			{[allProObj[0].p_purity_real_show]}
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			{[allProObj[0].p_purity_real_show]}
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	{[allProObj[0].p_purity_real_show]}
Golvatinib		++ VEGFR2, IC50: 16 nM			{[allProObj[0].p_purity_real_show]}
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	{[allProObj[0].p_purity_real_show]}
RAF265		++ VEGFR2, EC50: 30 nM			{[allProObj[0].p_purity_real_show]}
PD173074					{[allProObj[0].p_purity_real_show]}
BFH772		++++ VEGFR2, IC50: 3 nM			{[allProObj[0].p_purity_real_show]}
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			{[allProObj[0].p_purity_real_show]}
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	{[allProObj[0].p_purity_real_show]}
SAR131675			++ VEGFR3, IC50: 23 nM		{[allProObj[0].p_purity_real_show]}
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	{[allProObj[0].p_purity_real_show]}
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750), IC50: 2 nM EGFR (E746_A750/T790M), IC50: 14 nM						{[allProObj[0].p_purity_real_show]}
Daphnetin	+ EGFR, IC50: 7.67 μM					PKC,PKA	{[allProObj[0].p_purity_real_show]}
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		{[allProObj[0].p_purity_real_show]}
PD168393	++++ EGFR, IC50: 0.70 nM						{[allProObj[0].p_purity_real_show]}
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		{[allProObj[0].p_purity_real_show]}
Norcantharidin	✔						{[allProObj[0].p_purity_real_show]}
CL-387785	++++ EGFR, IC50: 370 pM						{[allProObj[0].p_purity_real_show]}
WHI-P154	+++ EGFR, IC50: 4 nM					Src,VEGFR	{[allProObj[0].p_purity_real_show]}
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	{[allProObj[0].p_purity_real_show]}
AG 555	+ EGFR, IC50: 0.7 μM						{[allProObj[0].p_purity_real_show]}
AG 494	+ EGFR, IC50: 1.2 μM						{[allProObj[0].p_purity_real_show]}
AG-556	+ EGFR, IC50: 5 μM						{[allProObj[0].p_purity_real_show]}
RG13022	+ EGFR, IC50: 4 μM						{[allProObj[0].p_purity_real_show]}
Tyrphostin RG 14620	✔						{[allProObj[0].p_purity_real_show]}
Vandetanib	+ EGFR, IC50: 500 nM						{[allProObj[0].p_purity_real_show]}
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		{[allProObj[0].p_purity_real_show]}
AZD3759	++++ EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM						{[allProObj[0].p_purity_real_show]}
Erlotinib	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Saracatinib	+++ EGFR (L861Q), IC50: 4 nM EGFR, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
AG1557	✔						{[allProObj[0].p_purity_real_show]}
Rociletinib	++ EGFR (wt), Ki: 303.3 nM EGFR (L858R/T790M), Ki: 21.5 nM						{[allProObj[0].p_purity_real_show]}
AG490	+ EGFR, IC50: 0.1 μM						{[allProObj[0].p_purity_real_show]}
Cetuximab	++++ EGFR, Kd: 0.39 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib	++ WT EGFR, IC50: 12.92 nM L858R/T790M EGFR, IC50: 11.44 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Chrysophanol	✔					mTOR	{[allProObj[0].p_purity_real_show]}
PD153035	++++ EGFR, Ki: 5.2 pM						{[allProObj[0].p_purity_real_show]}
Olmutinib	✔					BTK	{[allProObj[0].p_purity_real_show]}
WZ4002	++++ EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM						{[allProObj[0].p_purity_real_show]}
Icotinib	+++ EGFR, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Cyasterone	✔						{[allProObj[0].p_purity_real_show]}
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						{[allProObj[0].p_purity_real_show]}
WZ8040	✔						{[allProObj[0].p_purity_real_show]}
(-)-Epigallocatechin Gallate	✔						{[allProObj[0].p_purity_real_show]}
AG 18	+ EGFR, IC50: 35 μM						{[allProObj[0].p_purity_real_show]}
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						{[allProObj[0].p_purity_real_show]}
Falnidamol	✔						{[allProObj[0].p_purity_real_show]}
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	{[allProObj[0].p_purity_real_show]}
Butein	✔						{[allProObj[0].p_purity_real_show]}
Genistein	✔						{[allProObj[0].p_purity_real_show]}
SU5214	+ EGFR, IC50: 36.7 μM						{[allProObj[0].p_purity_real_show]}
Naquotinib	✔						{[allProObj[0].p_purity_real_show]}
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		{[allProObj[0].p_purity_real_show]}
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		{[allProObj[0].p_purity_real_show]}
Lazertinib	++++ WT EGFR, IC50: 76 nM L858R/T790M EGFR, IC50: 2 nM				++++ Del19/T790M, IC50: 1.7 nM		{[allProObj[0].p_purity_real_show]}
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						{[allProObj[0].p_purity_real_show]}
MTX-211	✔					PI3K	{[allProObj[0].p_purity_real_show]}
(E)-AG 99	✔						{[allProObj[0].p_purity_real_show]}
Licochalcone D	✔					Caspase,PARP	{[allProObj[0].p_purity_real_show]}
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM		{[allProObj[0].p_purity_real_show]}
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		{[allProObj[0].p_purity_real_show]}
Firmonertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Tyrphostin AG30	✔						{[allProObj[0].p_purity_real_show]}
EGFR-IN-12	++ EGFR, IC50: 21 nM						{[allProObj[0].p_purity_real_show]}
Mobocertinib	✔						{[allProObj[0].p_purity_real_show]}
(Rac)-JBJ-04-125-02	✔						{[allProObj[0].p_purity_real_show]}
(S)-Sunvozertinib	✔						{[allProObj[0].p_purity_real_show]}
BLU-945	✔						{[allProObj[0].p_purity_real_show]}
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			{[allProObj[0].p_purity_real_show]}
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			{[allProObj[0].p_purity_real_show]}
ARRY-380 analog				✔			{[allProObj[0].p_purity_real_show]}
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			{[allProObj[0].p_purity_real_show]}
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			{[allProObj[0].p_purity_real_show]}
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			{[allProObj[0].p_purity_real_show]}
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			{[allProObj[0].p_purity_real_show]}
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			{[allProObj[0].p_purity_real_show]}
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms	{[allProObj[0].p_purity_real_show]}
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^T790M, IC50: 0.79 nM EGFR^L858R/T790M, IC50: 0.51 nM		{[allProObj[0].p_purity_real_show]}
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	{[allProObj[0].p_purity_real_show]}
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			{[allProObj[0].p_purity_real_show]}
Tucatinib				+++ ErbB2, IC50: 8 nM			{[allProObj[0].p_purity_real_show]}
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Raf,Src	{[allProObj[0].p_purity_real_show]}
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			{[allProObj[0].p_purity_real_show]}
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	{[allProObj[0].p_purity_real_show]}
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			{[allProObj[0].p_purity_real_show]}
Afatinib dimaleate	++++ EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM			++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Canertinib dihydrochloride	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			{[allProObj[0].p_purity_real_show]}
Allitinib tosylate	++++ EGFR, IC50: 0.5 nM EGFR (T790M/L858R), IC50: 12 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			{[allProObj[0].p_purity_real_show]}
Afatinib	++++ EGFR (L858R), IC50: 10 nM EGFR (wt), IC50: 0.5 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			{[allProObj[0].p_purity_real_show]}
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			{[allProObj[0].p_purity_real_show]}
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			{[allProObj[0].p_purity_real_show]}
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	{[allProObj[0].p_purity_real_show]}
Brigatinib					+ EGFR(del19), IC50: 39.9 nM EGFR(C797S/T790M/del19), IC50: 67.2 nM	ALK,FLT3	{[allProObj[0].p_purity_real_show]}
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	{[allProObj[0].p_purity_real_show]}
EAI045					✔		{[allProObj[0].p_purity_real_show]}
Almonertinib					✔		{[allProObj[0].p_purity_real_show]}
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		{[allProObj[0].p_purity_real_show]}
EGFR-IN-7					++++ EGFR^L858R/T790M, IC50: 0.19 nM EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	c-Kit ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ c-Kit (Swiss 3T3), IC50: 1.8 μM	PDGFR	{[allProObj[0].p_purity_real_show]}
Masitinib	+ Kit, IC50: 200 nM		{[allProObj[0].p_purity_real_show]}
Motesanib Diphosphate	+++ Kit, IC50: 8 nM		{[allProObj[0].p_purity_real_show]}
Ki8751	++ c-Kit, IC50: 40 nM		{[allProObj[0].p_purity_real_show]}
Tivozanib	++ c-Kit, IC50: 78 nM		{[allProObj[0].p_purity_real_show]}
Pazopanib	+ c-Kit, IC50: 140 nM		{[allProObj[0].p_purity_real_show]}
Sitravatinib	+++ Kit, IC50: 6 nM		{[allProObj[0].p_purity_real_show]}
Pexidartinib	+++ Kit, IC50: 10 nM		{[allProObj[0].p_purity_real_show]}
Lactate	++++ c-Kit, IC50: 2 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Amuvatinib	+++ c-Kit (D816H), IC50: 10 nM		{[allProObj[0].p_purity_real_show]}
Imatinib Mesylate	+ c-Kit, IC50: 100 nM	PDGFR	{[allProObj[0].p_purity_real_show]}
AZD2932	+++ c-Kit, IC50: 9 nM		{[allProObj[0].p_purity_real_show]}
Axitinib	++++ Kit, IC50: 1.7 nM		{[allProObj[0].p_purity_real_show]}
Dovitinib	++++ c-Kit, IC50: 2 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Sunitinib	✔	FLT3	{[allProObj[0].p_purity_real_show]}
OSI-930	+ Kit, IC50: 80 nM		{[allProObj[0].p_purity_real_show]}
Telatinib	++++ c-Kit, IC50: 1 nM		{[allProObj[0].p_purity_real_show]}
Dasatinib monohydrate	++ c-Kit (D816V), IC50: 37 nM c-Kit (wt), IC50: 79 nM	Src	{[allProObj[0].p_purity_real_show]}
Dasatinib	++ c-Kit (D816V), IC50: 37 nM c-Kit (wt), IC50: 79 nM	Src	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

VEGFR-IN-1 生物活性

描述	VEGFR-IN-1 acts as a strong inhibitor of angiogenesis, exhibiting IC50 values of 0.02 µM for KDR, 0.18 µM for Flt-1, 0.24 µM for c-Kit, 7.3 µM for EGF-R, and 7 µM for c-Src, respectively^[1].

VEGFR-IN-1 参考文献

[1]Furet P, et al. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg Med Chem Lett. 2003;13(18):2967-2971.

VEGFR-IN-1 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.96mL

0.59mL

0.30mL

14.80mL

2.96mL

1.48mL

29.60mL

5.92mL

2.96mL

VEGFR-IN-1 技术信息

CAS号	269390-69-4
分子式	C₁₉H₁₆ClN₃O
分子量	337.803

别名	VEGFR Tyrosine Kinase Inhibitor II;Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor II
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 120 mg/mL(355.24 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

VEGFR-IN-1 {[allProObj[0].p_purity_real_show]}

VEGFR-IN-1 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

VEGFR-IN-1 质控信息

VEGFR-IN-1 生物活性

VEGFR-IN-1 参考文献

VEGFR-IN-1 实验方案

VEGFR-IN-1 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR-IN-1 {[allProObj[0].p_purity_real_show]}

VEGFR-IN-1 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

VEGFR-IN-1 质控信息

VEGFR-IN-1 生物活性

VEGFR-IN-1 参考文献

VEGFR-IN-1 实验方案

VEGFR-IN-1 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR-IN-1 纯度/质量文件产品仅供科研